Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2025; 17(11): 110638
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110638
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110638
Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study
Raafat SA Abdel Hafez, Department of Internal Medicine, Damanhour Teaching Hospital, Damanhour 22511, Egypt
Atteyat A Semeya, Department of Hepatology, Gastroenterology and Infectious Diseases, Benha Teaching Hospital, Benha 13511, Egypt
Rasha Elgamal, Department of Clinical Pathology, Faculty of Medicine, Suez University, Suez 43511, Egypt
Amira AA Othman, Department of Internal Medicine, Faculty of Medicine, Suez University, Suez 43511, Egypt
Author contributions: Abdel Hafez RS, Semeya AA, Elgamal R and Othman AA conceptualized and designed the study; Abdel Hafez RS, Semeya AA, Elgamal R and Othman AA collected and analyzed the data; Abdel Hafez RS and Othman AA performed statistical analysis and interpreted the results; Abdel Hafez RS, Semeya AA, Elgamal R and Othman AA drafted and critically revised the manuscript, all authors approved the final version to be published and agreed to be accountable for all aspects of the work.
Institutional review board statement: The study was conducted after obtaining approval from the Ethics Unite of Banha Teaching Hospitals, Egypt, Approval No. HB-000125.
Informed consent statement: All subjects were informed and gave their voluntary, written informed consent.
Conflict-of-interest statement: There are no conflicts of interest to report.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amira AA Othman, PhD, Department of Internal Medicine, Faculty of Medicine, Suez University, Cairo-Suez Road, Suez 43511, Egypt.
Received: June 11, 2025
Revised: July 27, 2025
Accepted: October 23, 2025
Published online: November 27, 2025
Processing time: 169 Days and 15.9 Hours
Revised: July 27, 2025
Accepted: October 23, 2025
Published online: November 27, 2025
Processing time: 169 Days and 15.9 Hours
Core Tip
Core Tip: Direct-acting antivirals (DAAs) are known to improve liver function in hepatitis C-related cirrhosis. However, their effect on portal hypertension and variceal rebleeding in genotype 4 patients remains underexplored. This multicenter retrospective study in Egypt reveals that DAA therapy is associated with a significantly lower risk of rebleeding and hepatic decompensation, supporting their role in secondary prevention post-variceal hemorrhage.